Try our beta test site
44 studies found for:    MEK162 OR binimetinib | Studies received from 01/01/2005 to 12/12/2020
Show Display Options
Rank Status Study
1 Recruiting MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Condition: Hepatic Impairment
Intervention: Drug: MEK162
Phase: Phase 1
Sponsor: Array BioPharma
Number Enrolled: 24
Primary Completion: March 31, 2017
First Received: January 16, 2014
2 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Lungcancer
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin
Phase: Phase 1
Sponsor/Collaborators: University Health Network, Toronto;   Novartis Pharmaceuticals
Number Enrolled: 30
Primary Completion: March 2018
First Received: April 9, 2014
3 Active, not recruiting MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Condition: Solid Tumor and Hematologic Malignancies
Intervention: Drug: MEK162
Phase: Phase 2
Sponsor: Array BioPharma
Number Enrolled: 110
Primary Completion: October 2015
First Received: June 20, 2013
4 Recruiting A Trial of mFOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers
Condition: Advanced KRAS Positive Metastatic Colorectal Cancer
Intervention: Drug: MEK162 and mFOLFIRI
Phase: Phase 1
Sponsor/Collaborators: University of Utah;   Array BioPharma
Number Enrolled: 30
Primary Completion: January 2020
First Received: November 12, 2015
5 Recruiting MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Condition: Biliary Tract Cancer
Intervention: Drug: MEK162+capecitabine
Phases: Phase 1 / Phase 2
Sponsor: Seoul National University Hospital
Number Enrolled: 35
Primary Completion: April 2017
First Received: May 13, 2016
6 Active, not recruiting A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumor
Intervention: Drug: MEK162
Phase: Phase 1
Sponsor: Array BioPharma
Number Enrolled: 21
Primary Completion: April 2014
First Received: November 8, 2011
7 Active, not recruiting A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Condition: Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
Intervention: Drug: BYL719 plus MEK162
Phases: Phase 1 / Phase 2
Sponsor: Array BioPharma
Number Enrolled: 138
Primary Completion: August 31, 2016
First Received: October 6, 2011
8 Terminated A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Conditions: Metastatic Pancreatic Adenocarcinoma;   BRAF Mutated Melanoma
Interventions: Drug: MEK162;   Drug: AMG 479
Phase: Phase 2
Sponsor: Array BioPharma
Number Enrolled: 77
Primary Completion: April 2015
First Received: March 22, 2012
9 Withdrawn Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
Condition: Cardiomegaly
Intervention: Drug: MEK162
Phase: Phase 2
Sponsor: Array BioPharma
Number Enrolled: 0
Primary Completion: May 2017
First Received: March 15, 2012
10 Not yet recruiting Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Conditions: Advanced Non-small Cell Lung Cancer;   KRAS Gene Mutation;   Lung Cancer
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Cisplatin
Phase: Phase 1
Sponsor: Swiss Group for Clinical Cancer Research
Number Enrolled: 18
Primary Completion: September 2019
First Received: November 14, 2016
11 Active, not recruiting First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Condition: Advanced Biliary Tract Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Drug: MEK162
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Memorial Sloan Kettering Cancer Center;   Array BioPharma
Number Enrolled: 42
Primary Completion: April 2017
First Received: April 5, 2013
12 Recruiting Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
Conditions: Low-Grade Gliomas;   Malignant Neoplasms, Brain;   Soft Tissue Neoplasms
Intervention: Drug: MEK162
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: Children's Hospital Los Angeles;   Dana-Farber Cancer Institute
Number Enrolled: 80
Primary Completion: December 2019
First Received: October 9, 2014
13 Terminated
Has Results
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162
Phases: Phase 1 / Phase 2
Sponsor: Array BioPharma
Number Enrolled: 38
Primary Completion: May 2015
First Received: February 21, 2013
14 Active, not recruiting MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: MEK inhibitor MEK162;   Drug: idarubicin;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Phase: Phase 1
Sponsor/Collaborators: Bruno C. Medeiros;   National Cancer Institute (NCI);   Stanford University
Number Enrolled: 19
Primary Completion: December 2019
First Received: January 28, 2014
15 Withdrawn Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Binimetinib;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis
Phase: Phase 1
Sponsor/Collaborators: Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Number Enrolled: 0
Primary Completion: June 2018
First Received: May 20, 2015
16 Active, not recruiting A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Condition: BRAF or NRAS Mutant Metastatic Melanoma
Intervention: Drug: MEK162
Phase: Phase 2
Sponsor: Array BioPharma
Number Enrolled: 183
Primary Completion: January 7, 2014
First Received: March 14, 2011
17 Completed MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Condition: Advanced Solid Tumors
Intervention: Drug: MEK162 + RAF265
Phase: Phase 1
Sponsor: Array BioPharma
Number Enrolled: 69
Primary Completion: September 2013
First Received: May 2, 2011
18 Recruiting MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Condition: Leukemia
Intervention: Drug: MEK 162
Phases: Phase 1 / Phase 2
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Array BioPharma
Number Enrolled: 57
Primary Completion: August 2018
First Received: March 13, 2014
19 Completed Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Conditions: Unspecified Adult Solid Tumor, Protocol Specific;   Solid Tumor
Intervention: Drug: BEZ235 + MEK162
Phase: Phase 1
Sponsor: Array BioPharma
Number Enrolled: 29
Primary Completion: March 2013
First Received: April 2, 2011
20 Active, not recruiting Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Conditions: Advanced Solid Tumors;   Selected Solid Tumors
Intervention: Drug: BKM120 + MEK162
Phase: Phase 1
Sponsor: Array BioPharma
Number Enrolled: 89
Primary Completion: March 2014
First Received: May 24, 2011

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.